TY - JOUR
T1 - The add-on effect of an intranasal antihistamine with an intranasal corticosteroid in Japanese cedar pollinosis
AU - Haruna, Takenori
AU - Kariya, Shin
AU - Higaki, Takaya
AU - Murai, Aya
AU - Kanai, Kengo
AU - Oka, Aiko
AU - Akamatsu, Maki
AU - Ando, Mizuo
AU - Nishizaki, Kazunori
AU - Okano, Mitsuhiro
N1 - Funding Information:
This work was supported in part by grants from the Japan Agency for Medical Research and Development (AMED) under Grant Number 21ek0410089h0001.
Publisher Copyright:
© 2022
PY - 2022
Y1 - 2022
N2 - Objective: Combination intranasal drugs with a corticosteroid and antihistamine are available in several countries with better effect than treatments with single agents. However, it remains unclear whether this effect is also seen in Japanese cedar pollinosis (JCP), the most prevalent seasonal allergic rhinitis in Japan. We investigated the effect of an add-on intranasal antihistamine with an intranasal corticosteroid in JCP during the pollen dispersal period. (UMIN000025508) Methods: We performed a double-blinded, randomized, placebo-controlled trial from March 1 to 14, 2017. Patients (n = 20 per group) received either a mometasone furoate nasal spray (MFNS) plus a levocabastine nasal spray (levocabastine group) or MFNS plus a placebo nasal spray (placebo group). The primary endpoint was the difference in the total nasal symptom score (TNSS) after treatment between the two groups. Differences in the total ocular symptom score, total symptom score, total medication score, total symptom-medication score, and five individual symptoms as well as safety were the secondary endpoints. Results: The change in the TNSS from baseline was significantly greater in the levocabastine group than in the placebo group. A significant reduction in the TNSS was observed more than 6 days earlier in the levocabastine group than in the placebo group. Such add-on effects were also seen in the secondary endpoints. Both treatments were well-tolerated. Conclusion: The intranasal antihistamine provided better control of not only nasal symptoms, but also of ocular symptoms, and decreased the need for rescue medications when added to intranasal corticosteroid treatment in JCP patients.
AB - Objective: Combination intranasal drugs with a corticosteroid and antihistamine are available in several countries with better effect than treatments with single agents. However, it remains unclear whether this effect is also seen in Japanese cedar pollinosis (JCP), the most prevalent seasonal allergic rhinitis in Japan. We investigated the effect of an add-on intranasal antihistamine with an intranasal corticosteroid in JCP during the pollen dispersal period. (UMIN000025508) Methods: We performed a double-blinded, randomized, placebo-controlled trial from March 1 to 14, 2017. Patients (n = 20 per group) received either a mometasone furoate nasal spray (MFNS) plus a levocabastine nasal spray (levocabastine group) or MFNS plus a placebo nasal spray (placebo group). The primary endpoint was the difference in the total nasal symptom score (TNSS) after treatment between the two groups. Differences in the total ocular symptom score, total symptom score, total medication score, total symptom-medication score, and five individual symptoms as well as safety were the secondary endpoints. Results: The change in the TNSS from baseline was significantly greater in the levocabastine group than in the placebo group. A significant reduction in the TNSS was observed more than 6 days earlier in the levocabastine group than in the placebo group. Such add-on effects were also seen in the secondary endpoints. Both treatments were well-tolerated. Conclusion: The intranasal antihistamine provided better control of not only nasal symptoms, but also of ocular symptoms, and decreased the need for rescue medications when added to intranasal corticosteroid treatment in JCP patients.
KW - Combination treatment
KW - Double-blinded randomized Placebo-controlled trial
KW - Intranasal antihistamine
KW - Intranasal corticosteroid
KW - Japanese cedar pollinosis
UR - http://www.scopus.com/inward/record.url?scp=85133209527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133209527&partnerID=8YFLogxK
U2 - 10.1016/j.anl.2022.05.007
DO - 10.1016/j.anl.2022.05.007
M3 - Article
C2 - 35768286
AN - SCOPUS:85133209527
SN - 0385-8146
JO - Auris Nasus Larynx
JF - Auris Nasus Larynx
ER -